FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2803886735> ?p ?o ?g. }

• W2803886735 endingPage "1403" @default.
• W2803886735 startingPage "1401" @default.
• W2803886735 abstract "Anti-CD19 chimeric antigen receptor (CAR) T cells (CART19) immunotherapy has proved to be extremely successful in B cell leukemia and lymphoma,1Ruella M. June C.H. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Curr. Hematol. Malig. Rep. 2016; 11: 368-384Crossref PubMed Scopus (54) Google Scholar and based on the beneficial results of several clinical trials, two CART19 products are now commercially available in the US.2Neelapu S.S. Locke F.L. Bartlett N.L. Lekakis L.J. Miklos D.B. Jacobson C.A. Braunschweig I. Oluwole O.O. Siddiqi T. Lin Y. et al.Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.N. Engl. J. Med. 2017; 377: 2531-2544Crossref PubMed Scopus (2816) Google Scholar, 3Schuster S.J. Svoboda J. Chong E.A. Nasta S.D. Mato A.R. Anak Ö. Brogdon J.L. Pruteanu-Malinici I. Bhoj V. Landsburg D. et al.Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.N. Engl. J. Med. 2017; 377: 2545-2554Crossref PubMed Scopus (1084) Google Scholar However, together with the striking antitumor effects, significant toxicities are associated with CAR T treatment—in particular, cytokine release syndrome (CRS) and neurotoxicity. CAR T toxicities are quite unique and specific to this potent treatment. Therefore, highly trained physicians are required to properly manage these patients. For this reason, the US Food and Drug Administration (FDA) approval for both Novartis and Kite/Gilead was contingent on a specific CAR T risk evaluation and mitigation strategy (REMS) management plan. Nevertheless, since the first pediatric patient treated with CART19 at the Children’s Hospital of Philadelphia, we have significantly improved our expertise on the management of CRS and neurotoxicity. However, we still do not have comprehensive knowledge on its pathogenesis.4Lee D.W. Gardner R. Porter D.L. Louis C.U. Ahmed N. Jensen M. Grupp S.A. Mackall C.L. Current concepts in the diagnosis and management of cytokine release syndrome.Blood. 2014; 124: 188-195Crossref PubMed Scopus (1663) Google Scholar, 5Maude S.L. Barrett D. Teachey D.T. Grupp S.A. Managing cytokine release syndrome associated with novel T cell-engaging therapies.Cancer J. 2014; 20: 119-122Crossref PubMed Scopus (519) Google Scholar, 6Brudno J.N. Kochenderfer J.N. Toxicities of chimeric antigen receptor T cells: recognition and management.Blood. 2016; 127: 3321-3330Crossref PubMed Scopus (779) Google Scholar Of note, preclinical murine models of CAR T therapy developed before human clinical use failed to predict the observed clinical toxicities with CART19. There is, therefore, an urgent need for preclinical models able to predict the toxicity of future CAR T products and to give deeper insights into the pathogenesis of CART19 toxicities. In this issue of Molecular Therapy, Pennell et al.7Pennell C.A. Barnum J.L. McDonald-Hyman C.S. Panoskaltsis-Mortari A. Riddle M.J. Xiong Z. Loschi M. Thangavelu G. Campbell H.M. Storlie M.D. et al.Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.Mol Ther. 2018; 26 (this issue): 1423-1434Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar describe the development of a new mouse model aimed to recapitulate key toxicities of chimeric antigen receptor immunotherapy, including CRS and neurotoxicity. The authors modified a previously developed humanized murine model where all mouse B cells also expressed human CD19 (hCD19).8Zhou L.J. Smith H.M. Waldschmidt T.J. Schwarting R. Daley J. Tedder T.F. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development.Mol. Cell. Biol. 1994; 14: 3884-3894Crossref PubMed Scopus (123) Google Scholar In the original homozygous model, hCD19 expression in mouse B cells was higher than in human B cells and murine CD19 expression and the absolute number of B cells were significantly reduced. Therefore, to overcome these issues, the authors generated a hemizygous version of the original model that resulted in an increased total B cell number and nearly physiologic levels of hCD19 expression. This new animal model was then used to assess the toxicity of anti-CD19 CAR T cells. The CAR19 construct used in this study features a 4-1BB costimulatory domain and, although not FDA-approved, is being tested in human clinical trials (ClinicalTrials.gov: NCT02028455). Murine T cells retrovirally transduced with the human CAR19 were generated and showed both in vitro and in vivo activation in the presence of hCD19+ murine B cells. Importantly, in vivo, CART19 cells significantly expanded in the spleen, leading to almost complete loss of B cells in the spleen and significant reduction in the peripheral blood. CART19 expansion and the induction of B cell aplasia are key characteristics of CART19 function in the clinic and reflect the strong T cell activation triggered by the engagement of the CAR construct (K.T. Mueller et al., 2016, Blood, abstract).9Kalos M. Levine B.L. Porter D.L. Katz S. Grupp S.A. Bagg A. June C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.Sci. Transl. Med. 2011; 3: 95ra73Crossref PubMed Scopus (1805) Google Scholar After demonstrating that, in this model, CART19 can efficiently recognize normal B cells, the authors began testing the anti-tumor efficacy. They engrafted the hCD19-humanized mice with a murine B cell lymphoma cell line (TBL12) that was engineered to express hCD19. Interestingly, in this model, CART19 were able to induce potent anti-lymphoma activity only when lymphodepletion was induced by cyclophosphamide, similar to observations in human adoptive cell therapy trials.10Laport G.G. Levine B.L. Stadtmauer E.A. Schuster S.J. Luger S.M. Grupp S. Bunin N. Strobl F.J. Cotte J. Zheng Z. et al.Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.Blood. 2003; 102: 2004-2013Crossref PubMed Scopus (159) Google Scholar, 11Kochenderfer J.N. Somerville R.P.T. Lu T. Shi V. Bot A. Rossi J. Xue A. Goff S.L. Yang J.C. Sherry R.M. et al.Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.J. Clin. Oncol. 2017; 35: 1803-1813Crossref PubMed Scopus (346) Google Scholar, 12Turtle C.J. Hanafi L.A. Berger C. Hudecek M. Pender B. Robinson E. Hawkins R. Chaney C. Cherian S. Chen X. et al.Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.Sci. Transl. Med. 2016; 8: 355ra116Crossref PubMed Scopus (664) Google Scholar, 13Heczey A. Louis C.U. Savoldo B. Dakhova O. Durett A. Grilley B. Liu H. Wu M.F. Mei Z. Gee A. et al.CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.Mol. Ther. 2017; 25: 2214-2224Abstract Full Text Full Text PDF PubMed Scopus (293) Google Scholar Importantly, the authors noted that a subset of mice was succumbing early after hCART19 infusion and speculated that they were experiencing CRS and/or neurotoxicity. To test the possible occurrence of on target and/or off tumor toxicity, non-tumor-bearing mice were injected with CART19 after lymphodepletion. Interestingly, in these mice, CART19 caused acute toxicity (weight loss, clinical signs) and deaths that correlated with higher CART19 and lymphodepletion doses. This is another important parallel of this preclinical murine model with human trials, where lymphodepletion and higher T cell doses correlate with severity of CRS.14Maude S.L. Frey N. Shaw P.A. Aplenc R. Barrett D.M. Bunin N.J. Chew A. Gonzalez V.E. Zheng Z. Lacey S.F. et al.Chimeric antigen receptor T cells for sustained remissions in leukemia.N. Engl. J. Med. 2014; 371: 1507-1517Crossref PubMed Scopus (3580) Google Scholar, 15Davila M.L. Riviere I. Wang X. Bartido S. Park J. Curran K. Chung S.S. Stefanski J. Borquez-Ojeda O. Olszewska M. et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci. Transl. Med. 2014; 6 (224ra25)Crossref PubMed Scopus (1771) Google Scholar, 16Hay K.A. Hanafi L.A. Li D. Gust J. Liles W.C. Wurfel M.M. López J.A. Chen J. Chung D. Harju-Baker S. et al.Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.Blood. 2017; 130: 2295-2306Crossref PubMed Scopus (592) Google Scholar In this context, the authors demonstrated the presence of intestinal-epithelial barrier damage, a finding that is not a classic sign of clinically evident CRS but may potentially be undiagnosed. Neurotoxicity is a major adverse effect of CAR T treatment6Brudno J.N. Kochenderfer J.N. Toxicities of chimeric antigen receptor T cells: recognition and management.Blood. 2016; 127: 3321-3330Crossref PubMed Scopus (779) Google Scholar, 17Gust J. Hay K.A. Hanafi L.A. Li D. Myerson D. Gonzalez-Cuyar L.F. Yeung C. Liles W.C. Wurfel M. Lopez J.A. et al.Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.Cancer Discov. 2017; 7: 1-16Crossref Scopus (732) Google Scholar that has been observed in both leukemia and lymphoma patients treated with CART19. The spectrum of neurotoxicity can span from mild confusion and agitation to aphasia, seizures, cerebral edema, coma, and, in rare cases, also death. In the present study, the authors observed behavioral abnormalities in mice treated with high CART19 doses, suggestive of neurotoxicity. Infiltration of T cells in the brain was detected, and fewer microglial cells were observed in the brain of mice experiencing CRS, potentially indicating cytotoxicity. A key unresolved issue is whether this finding is relevant to the neurotoxicity experienced in the clinic. A recent report from the Seattle group17Gust J. Hay K.A. Hanafi L.A. Li D. Myerson D. Gonzalez-Cuyar L.F. Yeung C. Liles W.C. Wurfel M. Lopez J.A. et al.Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.Cancer Discov. 2017; 7: 1-16Crossref Scopus (732) Google Scholar suggests that severe neurotoxicity is associated with increased blood-brain barrier permeability, high concentrations of cytokines in the cerebrospinal fluid, and endothelial damage. Diffuse activation of the immune system and, in particular, macrophages has been described as the main pathogenetic mechanism of CRS.18Teachey D.T. Rheingold S.R. Maude S.L. Zugmaier G. Barrett D.M. Seif A.E. Nichols K.E. Suppa E.K. Kalos M. Berg R.A. et al.Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.Blood. 2013; 121: 5154-5157Crossref PubMed Scopus (429) Google Scholar High levels of interleukin 6 (IL-6) and other innate immunity cytokines and markers of macrophage activation, such as ferritin, are found at very high levels in CRS.19Grupp S.A. Kalos M. Barrett D. Aplenc R. Porter D.L. Rheingold S.R. Teachey D.T. Chew A. Hauck B. Wright J.F. et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.N. Engl. J. Med. 2013; 368: 1509-1518Crossref PubMed Scopus (2505) Google Scholar, 20Fitzgerald J.C. Weiss S.L. Maude S.L. Barrett D.M. Lacey S.F. Melenhorst J.J. Shaw P. Berg R.A. June C.H. Porter D.L. et al.Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.Crit. Care Med. 2017; 45: e124-e131Crossref PubMed Scopus (284) Google Scholar, 21Teachey D.T. Lacey S.F. Shaw P.A. Melenhorst J.J. Maude S.L. Frey N. Pequignot E. Gonzalez V.E. Chen F. Finklestein J. et al.Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.Cancer Discov. 2016; 6: 664-679Crossref PubMed Scopus (636) Google Scholar In their study, Pennel and colleagues7Pennell C.A. Barnum J.L. McDonald-Hyman C.S. Panoskaltsis-Mortari A. Riddle M.J. Xiong Z. Loschi M. Thangavelu G. Campbell H.M. Storlie M.D. et al.Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.Mol Ther. 2018; 26 (this issue): 1423-1434Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar found that, in the colon and spleens of mice treated with high doses of CART19, there was activation of pathways of both the innate and adaptive immune system, including upregulation of IL-6 signatures. However, neither increased levels of cytokines nor macrophage activation markers were detected in the serum. An interesting observation is the clear role of interferon γ (IFN-γ) signaling in the development of CRS. T cell-secreted IFN-γ could be the trigger of innate immune system activation and of the subsequent release of IL-6. This is in line with the finding of increased serum IFN-γ in CRS patients and, the preclinical beneficial effect of the IL-2-inducible T cell kinase (ITK) inhibitor ibrutinib that is thought to be mediated by reduction of IFN-γ release.22Ruella M. Kenderian S.S. Shestova O. Klichinsky M. Melenhorst J.J. Wasik M.A. Lacey S.F. June C.H. Gill S. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.Leukemia. 2017; 31: 246-248Crossref PubMed Scopus (75) Google Scholar As mentioned, the management of CRS has significantly improved over the years due, in part, to the development of risk-adapted scoring systems and treatment algorithms.4Lee D.W. Gardner R. Porter D.L. Louis C.U. Ahmed N. Jensen M. Grupp S.A. Mackall C.L. Current concepts in the diagnosis and management of cytokine release syndrome.Blood. 2014; 124: 188-195Crossref PubMed Scopus (1663) Google Scholar A key player in the management of CRS is tocilizumab. It is indeed thanks to the use of this anti-IL-6 receptor antibody, which is routinely used for juvenile arthritis, that the first pediatric patient treated with CART19 was rescued from a very severe form of CRS.19Grupp S.A. Kalos M. Barrett D. Aplenc R. Porter D.L. Rheingold S.R. Teachey D.T. Chew A. Hauck B. Wright J.F. et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.N. Engl. J. Med. 2013; 368: 1509-1518Crossref PubMed Scopus (2505) Google Scholar The use of tocilizumab was guided by the timely cytokine measurements performed in our patients that revealed extremely elevated levels of IL-6 together with several other cytokines. Remarkably, also in the animal model developed by Pennel et al.,7Pennell C.A. Barnum J.L. McDonald-Hyman C.S. Panoskaltsis-Mortari A. Riddle M.J. Xiong Z. Loschi M. Thangavelu G. Campbell H.M. Storlie M.D. et al.Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.Mol Ther. 2018; 26 (this issue): 1423-1434Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar the use of an anti-IL-6 antibody reverses some of the consequences of CRS, such as weight loss. In summary, the authors of this paper developed an animal model able to recapitulate some aspects of CAR T-mediated toxicity. Other CRS models have been described with both CART1922Ruella M. Kenderian S.S. Shestova O. Klichinsky M. Melenhorst J.J. Wasik M.A. Lacey S.F. June C.H. Gill S. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.Leukemia. 2017; 31: 246-248Crossref PubMed Scopus (75) Google Scholar or HER2-CART,23Pegram H.J. Lee J.C. Hayman E.G. Imperato G.H. Tedder T.F. Sadelain M. Brentjens R.J. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.Blood. 2012; 119: 4133-4141Crossref PubMed Scopus (481) Google Scholar but these models either were developed using immunodeficient mice or used first-generation CARs. Other immunocompetent murine models have been developed for CAR T treatment,24Hu B. Ren J. Luo Y. Keith B. Young R.M. Scholler J. Zhao Y. June C.H. Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.Cell Rep. 2017; 20: 3025-3033Abstract Full Text Full Text PDF PubMed Scopus (231) Google Scholar, 25Davila M.L. Kloss C.C. Gunset G. Sadelain M. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.PLoS ONE. 2013; 8: e61338Crossref PubMed Scopus (125) Google Scholar, 26Kochenderfer J.N. Yu Z. Frasheri D. Restifo N.P. Rosenberg S.A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.Blood. 2010; 116: 3875-3886Crossref PubMed Scopus (252) Google Scholar but, no toxicity was observed in those systems. This is the first animal model able to reproduce both CRS and neurotoxicity after CART19. The reasons for the occurrence of CRS and neurotoxicity in this model, but not in others, are not completely clear. Several factors may interplay, including the use of intense lymphodepletion and the special interaction between hCD19 and human CAR19, a system that has been optimized to produce the greatest T cell activation. It is also surprising that a fully human CAR construct works so well in murine T cells and does not cause immune rejection of adoptively transferred T cells before the induction of antitumor effects and CRS. Despite the similarities of this model with human CART19 toxicities, several differences remain: the lack of IL-6, ferritin and C reactive protein elevation in the serum, and the lack of evident macrophage activation syndrome. These differences might be related to species-to-species variability but also the different function of murine versus human T cells and, not least, the lack of tumor cells in this model. Another aspect of this work is that it allows the potential pre-clinical evaluation of the toxicity of human CAR constructs. It would be very beneficial to extend this system to future CAR-antigen models and use it to predict human clinical toxicities. However, it might be difficult to recapitulate these results with target antigens whose expression pattern is less known as compared to CD19. This model would be difficult to use in novel CAR-antigen systems where the exact distribution of expression of the antigen is not completely known and would be part of the evaluation for on target off tumor effects. An optimization of this model could be the insertion of the human target gene X in the murine gene X in one allele at embryonic level so that the progeny will express both the human and murine target in all naturally expressing tissues. However, even in this case, murine toxicities may not overlap human ones as target expression can vary among different species. Overall, this report represents a milestone in the development of preclinical models able to predict human CAR T toxicity and efficacy and could be used to assess therapeutic approaches for CRS neurotoxicity and potentially acquire further insight on the mechanisms of CRS and/or neurotoxicity pathogenesis. The authors work under a research collaboration involving the University of Pennsylvania and the Novartis Institutes of Biomedical Research, Inc. M.R. and C.H.J. are inventors of intellectual property licensed by the University of Pennsylvania to Novartis. C.H.J. has sponsored research and equity from Tmunity Therapeutics. This work was supported by the Parker Institute for Cancer Immunotherapy (to M.R. and C.H.J.), NIH grant 5R01CA120409 (to C.H.J.), Gabrielle's Angel Foundation (to M.R.), the American Society of Hematology Scholar Award (to M.R.), and NIH NCI grants 1K99CA212302-01A1 (to M.R.) and P01CA214278-01 (to C.H.J.). Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic MicePennell et al.Molecular TherapyApril 6, 2018In BriefPennell et al. describe a human CD19 transgenic mouse model that mirrors the tumor efficacy and morbidities associated with CAR T cell therapy for human B cell malignancies. This model should allow approaches designed to reduce toxicity while preserving anti-tumor effects to be explored prior to testing in the clinic. Full-Text PDF Open Archive" @default.
• W2803886735 created "2018-06-01" @default.
• W2803886735 creator A5008558372 @default.
• W2803886735 creator A5088355904 @default.
• W2803886735 date "2018-06-01" @default.
• W2803886735 modified "2023-09-25" @default.
• W2803886735 title "Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans" @default.
• W2803886735 cites W1985579610 @default.
• W2803886735 cites W2045197676 @default.
• W2803886735 cites W2046562334 @default.
• W2803886735 cites W2049790267 @default.
• W2803886735 cites W2076560655 @default.
• W2803886735 cites W2082708772 @default.
• W2803886735 cites W2099570622 @default.
• W2803886735 cites W2105400883 @default.
• W2803886735 cites W2118796952 @default.
• W2803886735 cites W2167240384 @default.
• W2803886735 cites W2167550136 @default.
• W2803886735 cites W2340435799 @default.
• W2803886735 cites W2408097265 @default.
• W2803886735 cites W2499100065 @default.
• W2803886735 cites W2509364267 @default.
• W2803886735 cites W2519710256 @default.
• W2803886735 cites W2525215026 @default.
• W2803886735 cites W2602369513 @default.
• W2803886735 cites W2616637874 @default.
• W2803886735 cites W2756071038 @default.
• W2803886735 cites W2759643796 @default.
• W2803886735 cites W2763751953 @default.
• W2803886735 cites W2773804840 @default.
• W2803886735 cites W2775369717 @default.
• W2803886735 cites W2796175343 @default.
• W2803886735 cites W4234802323 @default.
• W2803886735 doi "https://doi.org/10.1016/j.ymthe.2018.05.005" @default.
• W2803886735 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5986966" @default.
• W2803886735 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29784587" @default.
• W2803886735 hasPublicationYear "2018" @default.
• W2803886735 type Work @default.
• W2803886735 sameAs 2803886735 @default.
• W2803886735 citedByCount "13" @default.
• W2803886735 countsByYear W28038867352019 @default.
• W2803886735 countsByYear W28038867352020 @default.
• W2803886735 countsByYear W28038867352021 @default.
• W2803886735 countsByYear W28038867352022 @default.
• W2803886735 crossrefType "journal-article" @default.
• W2803886735 hasAuthorship W2803886735A5008558372 @default.
• W2803886735 hasAuthorship W2803886735A5088355904 @default.
• W2803886735 hasBestOaLocation W28038867351 @default.
• W2803886735 hasConcept C174348530 @default.
• W2803886735 hasConcept C38652104 @default.
• W2803886735 hasConcept C41008148 @default.
• W2803886735 hasConcept C86803240 @default.
• W2803886735 hasConcept C95444343 @default.
• W2803886735 hasConceptScore W2803886735C174348530 @default.
• W2803886735 hasConceptScore W2803886735C38652104 @default.
• W2803886735 hasConceptScore W2803886735C41008148 @default.
• W2803886735 hasConceptScore W2803886735C86803240 @default.
• W2803886735 hasConceptScore W2803886735C95444343 @default.
• W2803886735 hasFunder F4320311601 @default.
• W2803886735 hasFunder F4320315119 @default.
• W2803886735 hasFunder F4320332161 @default.
• W2803886735 hasIssue "6" @default.
• W2803886735 hasLocation W28038867351 @default.
• W2803886735 hasLocation W28038867352 @default.
• W2803886735 hasLocation W28038867353 @default.
• W2803886735 hasOpenAccess W2803886735 @default.
• W2803886735 hasPrimaryLocation W28038867351 @default.
• W2803886735 hasRelatedWork W1641042124 @default.
• W2803886735 hasRelatedWork W1990804418 @default.
• W2803886735 hasRelatedWork W1993764875 @default.
• W2803886735 hasRelatedWork W2013243191 @default.
• W2803886735 hasRelatedWork W2046158694 @default.
• W2803886735 hasRelatedWork W2051339581 @default.
• W2803886735 hasRelatedWork W2082860237 @default.
• W2803886735 hasRelatedWork W2130076355 @default.
• W2803886735 hasRelatedWork W2151865869 @default.
• W2803886735 hasRelatedWork W2292806713 @default.
• W2803886735 hasVolume "26" @default.
• W2803886735 isParatext "false" @default.
• W2803886735 isRetracted "false" @default.
• W2803886735 magId "2803886735" @default.
• W2803886735 workType "article" @default.